We studied the pharmacokinetics and in vivo antifungal action of SCH39304, a new antifungal azole compound, in rabbits. It crossed the blood-cerebrospinal fluid barrier in the presence or absence of meningeal inflammation, reaching approximately 60% of the simultaneous concentrations in serum. In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space. SCH39304 and fluconazole both were highly effective against candida endophthalmitis, sterilizing the vitreous humor and the choroid and retina. SCH39304 suppressed candida endocarditis and reduced yeast counts in the kidney at all doses tested. SCH39304 was effective in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. Further investigations in humans are warranted.
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As a result of the increasing number of immunocompromised hosts and the frequent use of potent, broad-spectrum antibacterial agents, fungal infections have become increasingly prevalent. The standard treatment for most systemic mycotic infections remains amphotericin B, despite its toxicity. The azole compounds have advanced the treatment of fungal infections. Clotrimazole and miconazole proved to be effective for treating superficial dermatophyte and yeast infections. Initially, the azoles were used topically, but an intravenous preparation of miconazole showed some success against disseminated mycoses. Later, ketoconazole was licensed for use in mucocutaneous (5, 6 ) and deep-seated fungal infections. Ketoconazole was eventually shown to be an effective oral therapy for some disseminated mycoses (2) , notably paracoccidioidomycosis (11) , blastomycosis (1), histoplasmosis (1) , and coccidioidomycosis (14) .
Despite the success of ketoconazole, the medical community continues to search for new agents with lower toxicities, broader spectra of activity, and better pharmacokinetic profiles. Two azole compounds, fluconazole and itraconazole, have recently emerged which have been studied successfully in animal models (10 Antimicrobial assay. Levels of SCH39304 in serum, CSF, and urine were measured by high-pressure liquid chromatography at Schering-Plough. The procedure involved ether extraction in alkaline pH, reversed-phase column separation, and quantitation by determination of the A205. The limit of sensitivity of the method was approximately 0.5 ,ug of SCH39304 per ml of serum.
Production of cryptococcal meningitis. Beginning 1 day prior to infection and for the duration of the experiment, all animals received an intramuscular injection of cortisone acetate (2.5 mg/kg; Merck Sharp and Dohme, West Point, Pa.). Four-day-old cultures of Cryptococcus neoformans were suspended in 0.015 M phosphate-buffered saline, counted, and adjusted to 108 CFU/ml. Rabbits were sedated and inoculated intracisternally with 0.3 ml of the yeast suspension. On days 4, 7, 11, and 14 after inoculation, intracisternal taps were performed and approximately 0.3 ml of CSF was aspirated. The CSF was diluted in phosphatebuffered saline and cultured on Sabouraud agar with chloramphenicol. The results were expressed as log1o CFU per milliliter of CSF.
Production of disseminated candidiasis. For cardiac catheterization, rabbits were anesthetized and the right carotid artery was exposed. A polyethylene catheter (PE-50; ClayAdams, Parsippany, N.J.) was inserted and threaded to a point just across the aortic valve. The catheter was secured and left in place. The wound was closed with reflex staples. At 24 h after catheter insertion, 106 CFU of C. albicans suspended in 1 ml of phosphate-buffered saline was injected into the marginal ear vein.
Twenty-four hours after the last treatment, rabbits were sacrificed and the organs of interest and urine samples were removed. The heart was dissected and cardiac vegetations were harvested from the valve and from around the catheter tip. Each kidney was dissected, and the renal pelvis was swabbed for culture. Sections of each renal cortex, as well as the vitreous body, and the choroid and retina from each eye were collected.
All samples were weighed, homogenized, and cultured on Sabouraud agar with chloramphenicol. The urine and pelvic swab cultures were recorded as either positive or negative. For the Candida model, the Kruskal-Wallis rank sum test was used to analyze the pyelonephritis data. The endophthalmitis data were analyzed by the Fisher exact test (twosided). The endocarditis data were analyzed by using a one-way analysis of variance.
RESULTS
The 50% inhibitory concentrations of SCH39304 were 0.2 jig/ml for Candida albicans Carter and 6.25 ,ug/ml for Cryptococcus neoformans H99. No fungicidal activity was found against the Candida albicans strain when SCH39304 was tested at concentrations up to 100 jig/ml, but for Cryptococcus neoformans, the minimal fungicidal concentration was 25 ,ug/ml.
The pharmacokinetics of SCH39304 were determined in early experiments by using a single dose of drug. Figure 1 illustrates the pharmacokinetics of SCH39304 after a single dose of 20 mg/kg. In all animals, levels in serum rose over the first 6 h following ingestion and reached peak levels of about 15 ,ug/ml. Drugs could be measured in the CSF at the first time point sampled (2 h postdosing), regardless of the presence of meningeal inflammation. The median percent penetration from serum to CSF was 57% during the first 8 h after administration of a single dose. The presence of meningeal inflammation did not influence drug penetration into the CSF.
The pharmacokinetics of SCH39304 were also followed during the course of therapy in the experimental models of infection. Table 1 shows the drug concentrations in various body fluids after treatment with SCH39304. In all animals, oral administration produced measurable levels of SCH39304 in serum. In the Candida model, drug concentrations in serum 24 h after a single dose were not significantly different from the levels at 2 h. After a single dose or after seven daily doses, the concentrations in serum at 24 h also did not differ significantly. Drug levels in urine were determined 24 h after the last dose and showed high concentrations of SCH39304 (40 to 50 ,ug/ml) in all animals.
As shown in the bacterial meningitis model, the drug penetrated the CSF freely. SCH39304 concentrations were also measured in rabbits with fungal meningitis. High drug levels persisted in both the serum and CSF from 2 to 24 h after the administration of a single dose. Figure 2 shows the effects of various treatments on experimental cryptococcal meningitis in immunosuppressed rabbits. Initially, a dose of 20 mg of SCH39304 per kg per day was used. There was no difference between colony counts from treated animals and those from controls. Therefore, we increased the dose to 100 mg per day, or approximately 40 mg/kg per day. Over a 10-day observation period, colony counts in CSF from rabbits that received no treatment did not change. Only animals treated with amphotericin B had colony counts which were significantly different (P < 0.05) from those of untreated animals on day 7 of infection. By day 11, all treatment groups had colony counts which were statistically different (P < 0.05) from those of untreated animals. On day 14, the final reduction in colony counts was greatest in rabbits with amphotericin B therapy. Colony counts from animals treated with SCH39304 or fluconazole were not statistically different from each other at any point during the observation period. The rate of reduction of colony counts is represented by the slope of the linear portion of the growth curve for the infection in each rabbit. The mean slopes of the growth curves for rabbits in all three treatment groups were not statistically different after day 11.
Candida albicans was eliminated from ocular tissue by both SCH39304 and fluconazole (Fig. 3) . Treatment in untreated animals. Subsequently, lower doses were used to treat rabbits with this infection. SCH39304 significantly reduced yeast counts at all doses tested, and no dose was significantly better. Fluconazole was most effective at a dose of 20 mg/kg per day. Reduction of yeast counts in the kidney was greater with SCH39304 than with fluconazole with dosage regimens of 10 and 2.5 mg/kg per day, respectively (P < 0.03). For the different treatment regimens, the mean survivals were 93% for rabbits treated with SCH39304 and 83% for rabbits treated with fluconazole.
DISCUSSION
The correlation between in vitro antifungal activity of a therapeutic agent and in vivo efficacy is often imprecise. However, many findings on humans and animals indicate the importance of obtaining drug concentrations that are at least above the MIC for the causative organism. The first step in our evaluation was to examine the in vitro susceptibilities of the yeasts used in our model to SCH39304 and then to determine the pharmacokinetics of SCH39304 in rabbits. SCH39304 possessed reasonably good in vitro antifungal activity against our clinical isolates. The drug was reliably absorbed into the bloodstream of rabbits; rapid and persistent drug levels were also found in the CSF. 165, 1988) . The pharmacokinetics of SCH39304 were comparable to those of fluconazole. Both compounds showed low protein binding (10 to 20% for fluconazole and 10 to 15% for SCH39304), similarity in size (a molecular weight of 306 for fluconazole and a molecular weight of 331 for SCH39304), and good penetration into the CSF. In contrast, other azoles, such as ketoconazole, vibunazole, and itraconazole, penetrate poorly into the CSF (8) .
In vitro susceptibility testing of new antifungal agents is an important first step in the screening of antimicrobial agents, but the success of an agent depends on its in vivo activity. In this study we examined the azole compound SCH39304 in two established animal models of fungal infection. The cryptococcal meningitis model allows evaluation of drug activity in the central nervous system during significant immune suppression (9) (13, 15) . Our data on SCH39304 show that its in vitro activity, pharmacokinetics, and in vivo efficacy are similar to those of fluconazole in rabbits with experimental cryptococcal meningitis. It is likely that SCH39304 will also be effective in the management of human cryptococcal meningitis.
In rabbits with Candida infections, SCH39304 was also effective. In early Candida endophthalmitis the infection was significantly reduced in both ocular tissues studied. We did not measure SCH39304 concentrations in eye structures, but the ocular pharmacokinetics for other azoles have been determined (12) . Fluconazole penetrates well into several ocular tissues and fluids. A similar efficacy with fluconazole suggests that SCH39304 attains therapeutic drug levels in the eye. However, it should be mentioned that against a chronic Candida endophthalmitis model in rabbits, when therapy is delayed until 1 week after infection, the azoles are less successful (12) . SCH39304 has not been tested in this chronic ocular infection to determine whether it has any therapeutic advantage, but our initial results with this azole should encourage further evaluation.
Both SCH39304 and fluconazole significantly suppressed intravascular infection in rabbits with Candida endocarditis. These results are consistent with the long half-lives of the two drugs in serum. Their inability to completely eradicate this infection was not surprising, however, since they had only in vitro fungistatic activity against the Candida isolate that we used. However, these results indicate the need for further investigation into the medical management of Candida endocarditis with these long-acting azoles. 
